Skip to content
Peptide research

SNAP-8

Also known as Acetyl Octapeptide-3
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

What it is

SNAP-8 is a synthetic octapeptide marketed as a needle-free topical Botox alternative, blocking SNARE-complex acetylcholine release at nerve endings. Human evidence is weak, drawn mainly from multi-peptide studies; superior-potency claims are untested. The main gap is durability and independence of evidence, not acute danger; risks are mild irritation, but long-term data are scarce. Sold as an FDA-regulated cosmetic ingredient, not an FDA-approved drug.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Reduction of expression wrinkles (forehead lines, crow's feet, frown lines)

    Low

    Small human trials show eye-area improvement only; forehead and frown lines are unevidenced.

  • Superior potency compared to Argireline (Acetyl Hexapeptide-8)

    Speculative

    Claim comes from manufacturer data only; no peer-reviewed human comparison trial exists.

  • Non-invasive Botox-like muscle relaxation without loss of facial expressivity

    Speculative

    Mechanism-based only; no human EMG or skin-penetration study confirms this effect.

Evidence limits

Evidence Level
Moderate

The clinical evidence for SNAP-8 is consistent but limited in scope and rigor. The manufacturer's 28-day in-vivo study in 17 female volunteers is the primary efficacy data source, showing 34.98% mean wrinkle reduction (max -63.13%) at 10% solution, significantly outperforming Argireline (27.05%) and placebo (2.99%). A second manufacturer study at 3% solution showed up to 38% reduction. In vitro, SNAP-8 is approximately 30% more potent than Argireline (IC50 55 vs. 110 microM). Draelos et al. (2016) confirmed statistically significant facial line improvement in a 14-week multi-peptide trial. Shin et al. (2024) demonstrated wrinkle improvement and safety in a 24-subject microneedle delivery study. All studies report excellent safety with no adverse effects. However, there are no large-scale RCTs isolating SNAP-8, no long-term safety data beyond 28 days for the standalone ingredient, and core efficacy claims rest on manufacturer-sponsored data. The evidence is sufficient for cosmetic claims but far below pharmaceutical standards.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(4)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No known serious adverse effects

    Low
  • Mild skin irritation or redness in sensitive individuals

    Low
  • Limited long-term safety data

    Moderate
  • Peptide instability and reduced efficacy under improper conditions

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.